NKTX Nkarta Forecast, Technical & Fundamental Analysis
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies... Show more
NKTX is expected to report earnings to fall 1.51% to -36 cents per share on August 06
Q2'26
Est.
$-0.36
Q1'26
Missed
by $0.02
Q4'25
Missed
by $0.06
Q3'25
Beat
by $0.01
Q2'25
Beat
by $0.04
The last earnings report on May 12 showed earnings per share of -37 cents, missing the estimate of -34 cents. With 1.37M shares outstanding, the current market capitalization sits at 203.90M.
A.I. Advisor
published General Information
General Information
a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer
A.I.dvisor indicates that over the last year, NKTX has been loosely correlated with FATE. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTX jumps, then FATE could also see price increases.
NKTX's RSI Indicator ascending out of oversold territory
The RSI Oscillator for NKTX moved out of oversold territory on June 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 42 similar instances when the indicator left oversold territory. In of the 42 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for NKTX just turned positive on June 22, 2026. Looking at past instances where NKTX's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NKTX advanced for three days, in of 245 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 51 cases where NKTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on June 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NKTX as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
NKTX moved below its 50-day moving average on June 24, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NKTX crossed bearishly below the 50-day moving average on June 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NKTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for NKTX entered a downward trend on June 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.698) is normal, around the industry mean (20.978). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). NKTX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (366.957).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NKTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
